In a report released yesterday, Josh Jennings from TD Cowen reiterated a Buy rating on Ceribell, Inc., with a price target of $20.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Ceribell, Inc.’s strong performance and future potential. The company reported a significant 31% increase in Q3 revenue, surpassing market expectations, which demonstrates its growing market presence and successful adoption of its products. The increase in active accounts, reaching a record high, further supports the company’s expanding footprint and commercial traction.
Moreover, Ceribell’s gross margin remains robust at 88%, alleviating concerns about potential tariff impacts. The company’s upward revision of its 2025 sales guidance indicates confidence in its continued sales momentum and strategic initiatives to establish point-of-care EEG as a standard of care. Despite a net loss, the results were better than anticipated, and the company’s strong cash position provides a solid foundation for future growth. These factors collectively underpin Jennings’s positive outlook and Buy rating for Ceribell, Inc.
Jennings covers the Healthcare sector, focusing on stocks such as Medtronic, TransMedics Group, and Boston Scientific. According to TipRanks, Jennings has an average return of 0.6% and a 46.39% success rate on recommended stocks.